Nuo Therapeutics director nets 396 shares via options

Nuo Therapeutics director C. Eric Winzer reported routine equity compensation transactions.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nuo Therapeutics director C. Eric Winzer reported routine equity compensation transactions. On June 30, he exercised stock options for 40,000 shares of common stock at $1.00 per share. The issuer withheld 39,604 shares at the closing price of $1.01 to cover the exercise cost, leaving him with 396 newly issued shares.

Following these transactions, Winzer directly held 173,050 shares of common stock. He also received a new option grant on June 29 for 30,000 shares of common stock at an exercise price of $1.01 per share, vesting fully by June 30, 2027 and expiring on June 29, 2036.

Insider Trade Summary

40,000 shares exercised/converted

Exercise 4 txns

Insider WINZER C ERIC

Role Director

Type	Security	Shares	Price	Value
Exercise	Option to purchase common stock	40,000	$0.00	$0.00
Exercise	Common Stock	40,000	$1.00	$40K
Exercise Price or Tax Liability	Common Stock	39,604	$1.01	$40K
Grant/Award	Option to purchase common stock	30,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 30,000 contracts (Direct); Common Stock — 173,050 shares (Direct)

Footnotes (3)

F1. Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.
F2. 15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.
F3. The options fully vest as of June 30, 2027.

Key Figures

Options exercised: 40,000 shares Shares withheld: 39,604 shares Net shares received: 396 shares +5 more

8 metrics

Options exercised 40,000 shares Common stock options exercised on June 30, 2026 at $1.00

Shares withheld 39,604 shares Withheld to pay exercise price using $1.01 closing price

Net shares received 396 shares Net common shares from 40,000-share option exercise

Shares held after transaction 212,654 shares Director’s direct common stock holdings after June 30, 2026

New option grant size 30,000 options Options to purchase common stock granted June 29, 2026

New option exercise price $1.01 per share Exercise price for 30,000-share option grant

New option vesting date June 30, 2027 Options fully vest as of this date

New option expiration June 29, 2036 Expiration date for 30,000-share option grant

Key Terms

net exercise, tax-withholding disposition, Option to purchase common stock, exercise price, +1 more

5 terms

net exercise financial

"Represents a net exercise of outstanding stock options."

A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Option to purchase common stock financial

"Option to purchase common stock"

exercise price financial

"The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nuo Therapeutics (AURX) director C. Eric Winzer report?

Director C. Eric Winzer reported exercising options for 40,000 Nuo Therapeutics shares and a related tax-withholding disposition. He also reported receiving a new option grant for 30,000 shares, reflecting routine equity compensation activity rather than open-market buying or selling.

How many Nuo Therapeutics (AURX) shares did the director ultimately receive from the option exercise?

Winzer received 396 Nuo Therapeutics common shares from a net option exercise of 40,000 shares. The company withheld 39,604 shares to pay the exercise cost using a closing price of $1.01, leaving a relatively small net share increase.

What are the key terms of the new stock options granted to the Nuo Therapeutics (AURX) director?

Winzer received options for 30,000 Nuo Therapeutics shares with a $1.01 exercise price. These options vest fully by June 30, 2027 and expire on June 29, 2036, providing long-dated, time-vested equity compensation rather than immediate share ownership.

How many Nuo Therapeutics (AURX) shares does the director hold after these transactions?

After the reported transactions, Winzer directly holds 212,654 Nuo Therapeutics common shares. This figure reflects his position following the net exercise of 40,000 options and the associated tax-withholding share disposition recorded on June 30.

Was the Nuo Therapeutics (AURX) director’s Form 4 transaction an open-market sale of shares?

No, the disposition involved 39,604 shares withheld by the issuer to cover the option exercise cost at $1.01. This tax and exercise-related withholding is not an open-market sale and does not represent discretionary selling into the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/02/2026 - 08:59 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WINZER C ERIC

(Last)

(First)

(Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON

TEXAS

77054

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		M		40,000	A	$1	212,654	D
Common Stock	06/30/2026		F⁽¹⁾		39,604	D	$1.01	173,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to purchase common stock	$1	06/30/2026		M			40,000	01/01/2017⁽²⁾	06/30/2026	Common Stock	40,000	$0	0	D
Option to purchase common stock	$1.01	06/29/2026		A		30,000		06/30/2027⁽³⁾	06/29/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

2. 15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.

3. The options fully vest as of June 30, 2027.

	/s/ David Jorden, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR